Efficacy and safety of risdiplam in patients with type 1 spinal muscular atrophy: a 3-year open-label extension of the two-part, phase 2 FIREFISH trial
Maria Mazurkiewicz-Bełdzińska, Maria Mazurkiewicz-Bełdzińska, Laurent Servais, Giovanni Baranello et autres